BioSpace News Archive

Chemomab Therapeutics Ltd. today reported topline results from secondary analyses of its Phase 2a liver fibrosis trial assessing CM-101, its first-in-class CCL24-neutralizing antibody, in patients with non-alcoholic steatohepatitis (NASH).

BioVie Inc. today announced that an abstract highlighting baseline data from its multicenter, randomized, placebo-controlled Phase 3 study ( NCT04669028 ) of NE3107 in patients with mild to moderate Alzheimer’s disease will be presented.

Crescita Therapeutics Inc. today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 20, 2023.

Innovation Pharmaceuticals announced the United States Patent and Trade Office, on June 6, 2023, granted a patent, “Host Defense Protein Mimetics for Prophylaxis and/or Treatment of Inflammatory Diseases of the Gastrointestinal Tract,” and also recently issued a Notice of Allowance for the patent application, “Arylamide Compounds For Treatment Of Viral Infections.”

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the publication in Menopause.

Aethlon Medical, Inc., a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, announced that it is investigating the use of its Hemopurifier® in the organ transplant market, in addition to its ongoing studies in cancer and COVID-19.

Avantor, Inc. announced the global launch of the company’s Responsible Supplier Program designed to help reduce environmental impact and accelerate sustainable practices across the supply chain.

Virpax ® Pharmaceuticals, Inc. today announced that it has entered into a cooperative research and development agreement (CRADA) with the National Institute of Neurological Disorders and Stroke (NINDS).

Fresenius Kabi, a leading provider of injectable medicines, announced today it has launched the diagnostic pharmaceutical agent, Sincalide for Injection, an authorized generic for Bracco Diagnostics Inc.’s Kinevac® (Sincalide for Injection) product.

GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy of a single dose of AREXVY (respiratory syncytial virus vaccine, adjuvanted) against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 60 years and older over multiple RSV seasons and after annual revaccination.